Table 4.
Univariate analysis for overall survival.
| Variant | Hazard ratio | 95% CI (Lower) | 95% CI (Upper) | p-value |
|---|---|---|---|---|
| Age at diagnosis, n | ||||
| <40 y | 1 | |||
| 40–64 y | 2.162 | 1.093 | 4.275 | 0.027 |
| >64 y | 3.463 | 1.708 | 7.020 | 0.001 |
| Sex, n | ||||
| Male | 1 | |||
| Female | 0.881 | 0.660 | 1.177 | 0.393 |
| Extent of surgical resection, n | ||||
| Gross total resection | 1 | |||
| Subtotal resection | 1.334 | 0.878 | 2.026 | 0.177 |
| Biopsy | 1.677 | 1.187 | 2.370 | 0.003 |
| MGMT status, n | ||||
| Positive | 0.762 | 0.395 | 1.471 | 0.418 |
| Negative | 1 | |||
| Comorbidities at diagnosis, n | ||||
| Diabetes Mellitus | 1.478 | 1.055 | 2.072 | 0.023 |
| Hypertension | 1.363 | 1.028 | 1.806 | 0.031 |
| Ischemic heart disease | 3.493 | 1.825 | 6.683 | 0.000 |
| RT total dose (Gy), n | ||||
| ≥56 | 1 | |||
| 36–50 | 1.789 | 1.081 | 2.962 | 0.024 |
| ≤32 | 6.556 | 2.638 | 16.297 | 0.000 |
| No. of adjuvant Temozolomide cycles*, n | ||||
| 0 | 1 | |||
| 1–3 | 0.896 | 0.534 | 1.506 | 0.680 |
| 4–6 | 0.694 | 0.400 | 1.202 | 0.193 |
| 7–9 | 0.372 | 0.193 | 0.718 | 0.003 |
| ≥10 | 0.180 | 0.099 | 0.327 | 0.000 |
| No. of Patients who switched to 2nd line therapy | ||||
| Yes | 0.445 | 0.334 | 0.594 | 0.000 |
| No | 1 | |||
| Pauses during RT | ||||
| Yes | 0.817 | 0.507 | 1.317 | 0.407 |
| No | 1 | |||
| Steroid use during RT | ||||
| Yes | 1.453 | 0.880 | 2.398 | 0.144 |
| No | 1 | |||
| *Post concomitant therapy with RT + TMZ. | ||||
Hazard ratio (HR) less than 1 – better overall survival, > 1 – worse overall survival; P-value < 0.05 – statistically significant.